Argenx
ARGX
#527
Rank
NZ$68.40 B
Marketcap
$1,144
Share price
3.88%
Change (1 day)
72.73%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2024 (TTM): -NZ$0.11 Billion

According to Argenx 's latest financial reports the company's current earnings are NZ$1.85 Billion. In 2023 the company made an earning of -NZ$0.54 Billion, an increase over its 2022 earnings that were of -NZ$1.3 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -NZ$0.11 Billion-80.11%
2023 -NZ$0.54 Billion-58.25%
2022 -NZ$1.3 Billion
2019 -NZ$0.36 Billion124.95%
2018 -NZ$0.16 Billion132.04%
2017 -NZ$67.61 Million54.86%
2016 -NZ$43.66 Million33%
2015 -NZ$32.83 Million13.63%
2014 -NZ$28.89 Million46.25%
2013 -NZ$19.76 Million